SUPN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SUPN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-03-29), Supernus Pharmaceuticals's share price is $34.08. Supernus Pharmaceuticals's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.90. It's Price-to-Owner-Earnings for today is 37.87.
The historical rank and industry rank for Supernus Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:
During the past 13 years, the highest Price-to-Owner-Earnings of Supernus Pharmaceuticals was 179.75. The lowest was 7.21. And the median was 19.42.
As of today (2024-03-29), Supernus Pharmaceuticals's share price is $34.08. Supernus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00. Therefore, Supernus Pharmaceuticals's PE Ratio for today is At Loss.
As of today (2024-03-29), Supernus Pharmaceuticals's share price is $34.08. Supernus Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $0.27. Therefore, Supernus Pharmaceuticals's PE Ratio without NRI for today is 128.12.
During the past 13 years, Supernus Pharmaceuticals's highest PE Ratio without NRI was 163.15. The lowest was 7.45. And the median was 27.58.
The historical data trend for Supernus Pharmaceuticals's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Supernus Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 34.08 | / | 0.90 | |
= | 37.87 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (NAS:SUPN) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Tami Tillotson Martin | officer: Sr. V.P., Regulatory Affairs | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Newhall Charles W Iii | director | 1119 ST PAUL ST, BALTIMORE MD 21202 |
Frederick M. Hudson | director | 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Frank Mottola | officer: Sr VP, Quality, GMP Oper. & IT | 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Bethany Sensenig | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Jack A. Khattar | director, officer: President, CEO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Timothy C Dec | officer: Senior Vice-President & CFO | C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
Jonathan Rubin | officer: SVP, Chief Medical Officer | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Schwabe Stefan K.f. | officer: Executive Vice President R&D | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Gregory S Patrick | officer: VP, Chief Financial Officer | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
James Patrick Kelly | officer: Executive Vice-President & CFO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Carrolee Barlow | director | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Victor Vaughn | officer: Sr. VP of Sales | C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850 |
M James Barrett | director, 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By PRNewswire 10-27-2022
By sperokesalga 04-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.